Literature DB >> 8770530

Diabetes mellitus in schizophrenic patients.

S Mukherjee1, P Decina, V Bocola, F Saraceni, P L Scapicchio.   

Abstract

Studies conducted in the United States and Japan indicate that diabetes mellitus is more common among schizophrenic patients than among the general population. The prevalence of known diabetes was examined in 95 schizophrenic patients aged 45 to 74 years admitted to a long-term care facility in Italy. The overall prevalence of diabetes was 15.8% (95% confidence interval, 12.1% to 19.5%), and increased from 0% in those younger than 50 years, through 12.9% in the 50- to 59-year age group, and to 18.9% in the 60- to 69-year age group, and then decreased to 16.7% in those aged 70 to 74 years. These rates are considerably higher than those reported from population surveys in Italy, and indicate that a higher prevalence of diabetes in schizophrenic patients may be a universal phenomenon. The clinical picture indicated that in all cases this was the common variant of type II (non-insulin-dependent) diabetes mellitus. Diabetes was more common in patients not receiving neuroleptics than in those who were receiving such treatment. There was no association between diabetes and the use of anticholinergic drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770530     DOI: 10.1016/s0010-440x(96)90054-1

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  58 in total

Review 1.  The interface of psychiatric disorders and diabetes mellitus.

Authors:  M K Popkin; E A Colon
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

Review 2.  Metabolic consequences of atypical antipsychotic drugs.

Authors:  Harold E Lebovitz
Journal:  Psychiatr Q       Date:  2003

Review 3.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

4.  Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis.

Authors:  Sabrina D Robertson; Heinrich J G Matthies; W Anthony Owens; Vidiya Sathananthan; Nicole S Bibus Christianson; J Phillip Kennedy; Craig W Lindsley; Lynette C Daws; Aurelio Galli
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

5.  Symptom control and patient adherence to treatment: key goals in the treatment of psychosis.

Authors:  Marios Adamou
Journal:  Psychiatry (Edgmont)       Date:  2004-07

6.  Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.

Authors:  Jaana Suvisaari; Jonna Perälä; Samuli I Saarni; Tommi Härkänen; Sami Pirkola; Matti Joukamaa; Seppo Koskinen; Jouko Lönnqvist; Antti Reunanen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

Review 7.  Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents.

Authors:  David C Henderson
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

8.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

Review 9.  Brain foods: the effects of nutrients on brain function.

Authors:  Fernando Gómez-Pinilla
Journal:  Nat Rev Neurosci       Date:  2008-07       Impact factor: 34.870

Review 10.  Lipid effects of psychiatric medications.

Authors:  Junzo Watanabe; Yutaro Suzuki; Toshiyuki Someya
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.